Boehringer Ingelheim

Hikma acquires Roxane Laboratories

Wednesday, July 29, 2015 11:46 AM

Hikma Pharmaceuticals, a multinational pharmaceutical group, has agreed to acquire Boehringer Ingelheim Roxane and Roxane Laboratories from Boehringer Ingelheim. Roxane is a well-established U.S. specialty generics company with a highly differentiated product portfolio and best-in-class R&D capabilities.

More... »


Enanta Pharmaceuticals appoints Nathalie Adda chief medical officer

Wednesday, July 8, 2015 10:46 AM

Enanta Pharmaceuticals, a R&D-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has appointed Nathalie Adda, M.D., senior vice president and chief medical officer, responsible for clinical and regulatory affairs.

More... »


Report: Innovation trends in treatments for rare diseases and widespread conditions

Wednesday, June 17, 2015 08:45 AM

The antibiotics market is at risk of losing another decade to inadequate levels of research and innovation, according to international intellectual property firm Marks & Clerk’s new report From rare to routine—medicines for rare diseases, vaccines and antibiotics. Research highlights the striking difference between research levels into rare diseases, vaccines and antibiotics across the globe.

More... »

Eureka Therapeutics, Boehringer Ingelheim collaborate on cancer treatments

Friday, May 22, 2015 01:42 PM

California-based Eureka Therapeutics and Germany-based Boehringer Ingelheim have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology.

More... »

Icon executives release book for re-engineering clinical trials

Wednesday, April 15, 2015 12:50 PM

Global CRO Icon of Dublin, Ireland, has released the book Re-Engineering Clinical Trials, edited and co-authored by Brendan Buckley, Icon’s chief medical officer, and Peter Schüler, ICON’s senior vice president of global medical and safety services.

More... »

FDA approves record 41 new drugs in 2014, over 40% for rare diseases

Friday, January 16, 2015 02:52 PM

Pharmaceutical innovation had a banner year in 2014, as the FDA approved 41 novel drugs and biologics—the largest number in 18 years and a 52% increase from the 27 approved in 2013.

More... »

Boehringer Ingelheim, WellPoint, HealthCore collaborate

Monday, November 17, 2014 02:34 PM

Boehringer Ingelheim Pharmaceuticals (BIPI); WellPoint, an Indiana-based, U.S. health benefit company; and HealthCore, a Wilmington, Del.-based wholly-owned subsidiary of WellPoint, are launching a research project to identify and address unmet medical needs.

More... »

Cloud Pharmaceuticals ratifies board of directors

Friday, November 7, 2014 01:42 PM

Cloud Pharmaceuticals, a therapeutics company focused on cloud-based drug design and development, has ratified its board of directors. Members of the board include Cloud Pharmaceuticals chairman and CEO Ed Addison, chief scientific officer Shahar Keinan, Ph.D., and chief information officer Lawrence Husick. Other members of the board include:

More... »

Finding Opportunities in the Information Value Chain

Monday, October 27, 2014 07:00 AM

At a recent meeting with a molecular diagnostics client, I went around the room and asked each executive to tell me what business he/she was in.

More... »

Boehringer Ingelheim, CureVac collaborate on lung cancer immunotherapy

Thursday, September 18, 2014 01:39 PM

Boehringer Ingelheim and CureVac, a clinical stage biopharmaceutical company based in Tubingen, Germany, have announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer.

More... »


CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs